Preview

Rational Pharmacotherapy in Cardiology

Advanced search

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS

https://doi.org/10.20996/1819-6446-2011-7-1-89-93

Full Text:

Abstract

Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy in patients with cardioascular diseases are discussed. Role of clopidogrel in contemporary antiplatelet therapy is focused on, especially in the aspect of the problem of aspirin resistance. Chronology of the clopidogrel generics appearance and prospects of their use is presented.

About the Author

O. V. Gaisenok
Joint Hospital and Polyclinic, Department of Affairs of the President of Russian Federation
Russian Federation


References

1. Oshchepkova E.V. Five-year results of implementation of the federal target program Prevention and Treatment of Arterial Hypertension in Russian Federation (2002-2006). Ter Arkh. 2007;79(9):25-30. Russian (Ощепкова Е.В. Пятилетние итоги реализации федеральной целевой программы “Профилактика и лечение артериальной гипертонии в Российской Федерации” (2002–2006 гг). Тер архив 2007; 9: 25-30).

2. Burke A.P., Farb A., Tang A.L. et al. Coronary plaque erosion without rupture into a lipid score. A frequent cause of coronary thrombosis in sudden cardiac death. Circulation 1996; 93(7): 1354-1363.

3. Mamontova N.V., Kirichuk V.F. Blood rheology and their abnormalities in patients with coronary heart disease (literature review). Saratov Journal of Medical Scientific Research 2007; 3(1): 16-24. Russian (Мамонтова Н.В., Киричук В.Ф. Реологические свойства крови и их нарушения у больных ишемической болезнью сердца (обзор литературы). Саратовский научно-медицинский журнал 2007; 3(1): 16-24).

4. Mueller M.R., Salat A., Stangl P. et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78(3): 1003–7.

5. Eikelboom J.W., Hirsh J., Weitz J.I. et al. Aspirin resistance and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk of cardiovascular outcomes. Circulation 2002; 105(14): 1650–5.

6. Bhatt D.L., Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nature Reviews 2003; 2(1): 15-28.

7. Gum P.A., Kottke-Marchant K., Welsh P.A. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41(6): 961–5.

8. Ushkalova E.A. Aspirin resistance: mechanisms of development, methods of detection and clinical significance. Farmateka 2006; 13: 35–41. Russian (Ушкалова Е.А. Аспиринорезистентность: механизмы развития, методы определения и клиническое значение. Фарматека 2006; 13: 35–41).

9. Ainetdinova D.H., Udovichenko A.Е., Sulimov V.A. Antiplatelet therapy resistance in patients with acute coronary syndrome with ST-segment elevation. Rational Pharmacother Card 2008;2:23-29. Russian (Айнетдинова Д.Х., Удовиченко А.Е., Сулимов В.А. Резистентность к антитромбоцитарным препаратам у больных острым коронарным синдромом с подъемом сегмента ST. РФК 2008;2:23-29).

10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348 (9038): 1329 - 39.

11. Baryshnikova G.A. Role of Clopidogrel in the treatment and prevention of cardiovascular diseases. Consilium Medicum 2009; 11(10): 130-137. Russian (Барышникова Г.А. Роль клопидогрела в лечении и профилактике сердечно-сосудистых заболеваний. Consilium Medicum 2009; 11(10): 130-137).

12. Shalnova S.A., Deev A.D, Vikhirova O.V. et al. The prevalence of hypertension in Russia: the awareness, treatment, control. Profilaktika zabolevaniy i ukreplenie zdorovya 2001; 2: 3-7. Russian (Шальнова С.А., Деев А.Д, Вихирова О.В. и др. Распространенность АГ в России: информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья 2001; 2: 3-7).

13. Spending on health: a global overview. WHO Fact Sheet 2007; 319. Available on http://www.who.int/mediacentre/factsheets/fs319.pdf

14. IMS Health lowers 2009 global pharmaceutical market forecast to 2.5–3.5 percent growth. IMS Press Releases. Available on http://www.imshealth.com/portal/site/imshealth/menuitem.a46c6d4df3d b4b3d88f611019418c22a/?vgnextoid=1e61fa8adbec0210VgnVCM100000ed152ca2RCRD.htm

15. Kenneth K, editor. Handbook for curbing corruption in public procurement. Berlin: Transparency International; 2006.

16. Report of the Regional Centre for Monitoring Drug Safety in the Northwestern Federal District and the city of St. Petersburg. Rating domestic and foreign leaders among the pharmaceutical manufacturers in terms of poor-quality products according to the Federal Service for Supervision of Health and Social Development in the first half of 2009. Available on: http://labclinpharm.ru/rating_mp.html. Russian (Отчет Регионального Центра мониторинга безопасности лекарственных средств в Северо-Западном федеральном округе РФ и городе Санкт-Петербурге. Рейтинг отечественных и зарубежных лидеров среди фармацевтических производителей по объемам недоброкачественной продукции по данным Федеральной службы по надзору в сфере здравоохранения и социального развития за первое полугодие 2009 года. Доступно на: http://labclinpharm.ru/rating_mp.html).


For citation:


Gaisenok O.V. THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS. Rational Pharmacotherapy in Cardiology. 2011;7(1):89-93. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-1-89-93

Views: 391


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)